Document:

EX-10.16

 Exhibit 10.16 

SECOND AMENDMENT TO LICENSE AGREEMENT 

This amendment, dated 9 August, 2013, is by and between Cytopherx (“LICENSEE”) and the Regents of the University of Michigan
(“MICHIGAN”). 
 WHEREAS, Nephrion, now doing business as Cytopherx (“LICENSEE”) and MICHIGAN entered into a license
agreement dated 17 August 2007 and entered into a First Amendment March 23, 2011 (collectively the “License Agreement”); and 

WHEREAS, MICHIGAN and LICENSEE desire to modify certain provisions of the License Agreement as provided herein. 

NOW THEREFORE, MICHIGAN and LICENSEE hereby agree as follows: 

1. Existing Paragraph 2.10 shall be deleted in its entirety and replaced with the following: 

2.10 “Technology” means MICHIGAN’s legal rights under the patent laws of the United States or relevant countries for all of the
following: 
 (1) the United States and foreign patents and/or patent applications listed in Appendix A; 

(2) United States and foreign patents issued (i) from the applications listed in Appendix A, (ii) from divisionals and continuations
of the patents and/or patent applications listed in Appendix A (including continuations and divisionals that claim priority to the patents and/or patent applications listed in appendix A), and (iii) from continuations-in-part of the patents and/or patent applications listed in Appendix A or claim priority to the patents and/or patent applications listed in Exhibit A to the extent that claims are directed to
subject matter specifically described in the patents and/or patent applications listed in Appendix A; 
 (3) claims in all foreign patent
applications, and of the resulting patents, which are directed to subject matter specifically described in the United States patents and/or patent applications described in (1) or (2) above; 

(4) claims in all patent applications and of the resulting patents, which are directed to subject matter specifically described as of the
Effective Date in the MICHIGAN Office of Technology Transfer files listed in Appendix A; and 
 (5) any reissued and reexamined patents, and
extensions (including supplementary protection certificates or equivalents thereof), of the patents described in (1), (2), (3) or (4) above. 

2. Beginning in 2012, the annual minimum royalties due under Paragraph 4.3 shall be reduced to $12,500. Annual fees for 2012 and 2013 shall be
deferred and paid in full with the 2014 Annual Fee. For clarity, in June 30, 2014, a total of $25,000 shall be due. 

 3. Patent costs owed by LICENSEE as of July 31, 2013 of $5126.10 shall be payable
December 31, 2013 or within ten day s of closing of additional financing round, whichever comes earlier. All ongoing costs incurred by MICHIGAN after July 31, 2013 shall be paid according to Paragraph 10,4, 

4. Except as specifically modified and amended above, all other terms and conditions of the License Agreement remain unchanged and in effect
and are hereby ratified and adopted as though fully set forth herein. 
 IN WITNESS WHEREOF, the parties have entered into this Amendment to
the Amended Agreement as of the date and year first above-written. 
  

									
	CYTOPHERX, INC.	 		 	THE REGENTS OF THE UNIVERSITY OF MICHIGAN
					
	By:	 	 /s/ Shawn O’Brien
	 		 	By:	 	 /s/ Ruth L. Rasor

	Title:	 	Director of Finance	 		 	 Title:
	 	Director of Licensing, UM Technology Transfer

  
 2 

 APPENDIX A: MICHIGAN FILES 1621, 2175, 2305 and 3718 

PATENT APPLICATIONS, ISSUED PATENTS AND MICHIGAN FILES 
  

											
	 File Number
	 	 Status
	 	 Filing Date
	 	 Serial Num
	 	 Issue Date
	 	 Patent Num

	1621	 	Issued	 	4/23/99	 	09/553,772	 	5/13/03	 	6,561,997
	162 1 cl	 	Issued	 	3/28/03	 	10/402,912	 	7/05/05	 	6,913,588
	2175	 	Issued	 	8/30/01	 	09/941,987	 	11/25/03	 	6,653,131
	2305	 	Issued	 	2/25/03	 	10/372,303	 	10/28/08	 	7,442,546

  
 3EX-10.17

 Exhibit 10.17 

THIRD AMENDMENT TO LICENSE AGREEMENT 

This amendment dated 31 July, 2014, is by and between Cytopherx (“LICENSEE”) and the Regents of the University of Michigan
(“MICHIGAN”). 
 WHEREAS, Nephrion, now doing business as Cytopherx (“LICENSEE”) and MICHIGAN entered into a license
agreement dated 16 October 2007, entered into a First Amendment 22 March 2011, and entered into a Second Amendment 8 August 2013 (collectively the “License Agreement”); and 

WHEREAS, MICHIGAN and LICENSEE desire to modify certain provisions of the License Agreement as provided herein. 

NOW THEREFORE, MICHIGAN and LICENSEE hereby agree as follows: 

1. The annual minimum royalties due under Paragraph 4.3 for 2014 shall be deferred and paid in full with the 2015 Annual Fee. For clarity, in
June 30, 2015, a total of $70,000 shall be due. 
 2. Patent costs owed by LICENSEE as of July 31, 2014 of $31,316.90 shall be
payable in two installments of $15,658.45 on August 31, 2014 and September 30, 2014. All ongoing costs incurred by MICHIGAN after July 31, 2014 shall be paid according to Paragraph 7.3. 

3. Except as specifically modified and amended above, all other terms and conditions of the License Agreement remain unchanged and in effect
and are hereby ratified and adopted as though fully set forth herein. 
 IN WITNESS WHEREOF, the parties have entered into this Amendment to
the Amended Agreement as of the date and year first above-written. 
  

									
	CYTOPHERX, INC.	 		 	THE REGENTS OF THE UNIVERSITY OF MICHIGAN
					
	By:	 	 /s/ Charles J. Fisher, Jr.
	 		 	By:	 	 /s/ Kenneth J. Nisbet

	Title: Executive Chair	 		 	Title: Associate VP for Research, UM Tech Transfer

  

 APPENDIX A: MICHIGAN FILES 37178 

PATENT APPLICATIONS, ISSUED PATENTS AND MICHIGAN FILES 
  

																	
	File Number	  	Status	  	Filing Date	  	Serial Num	 	  	Issue Date	 	  	Patent Num	 
	 3718
	  	Issued	  	5/29/08	  	 	12/201,576	 	  	 	8/28/12	 	  	 	8,251,941	 
		  	Issued	  	6/30/10	  	 	12/827,594	 	  	 	4/23/12	 	  	 	8,425,445	 
		  	Issued	  	6/30/10	  	 	12/827,601	 	  	 	4/30/13	 	  	 	8,430,832	 
		  	Issued	  	6/30/10	  	 	12/827,606	 	  	 	4/2/13	 	  	 	8,409,126	 
		  	Issued	  	6/30/10	  	 	13/593,169	 	  	 	4/23/13	 	  	 	8,425,447	 
		  	Pending	  	4/15/11	  	 	13/087,995	 	  				  			
		  	Pending	  	6/25/12	  	 	13/531,870	 	  				  			
		  	Pending	  	6/25/12	  	 	13/531,872	 	  				  			
		  	Pending	  	8/23/12	  	 	13/593,127	 	  				  			

  
 2EX-10.18

 Exhibit 10.18 

FOURTH AMENDMENT TO LICENSE AGREEMENT 

OTT File 0671 
 This
amendment, dated June 20, 2016, is by and between Cytopherx, Inc. (“LICENSEE”) and the Regents of the University of Michigan (“MICHIGAN”). 

WHEREAS, Nephrion, Inc., and MICHIGAN entered into an Amended and Restated License Agreement on October 17, 2007, entered into a First
Amendment dated March 23, 2011, entered into a Second Amendment August 9, 2013 and entered into a Third Amendment 31 July 2014 (collectively the “License Agreement”); 

WHEREAS, Nephrion, Inc. changed its name to Cytopherx, Inc. on or about October 1, 2009; and 

WHEREAS, MICHIGAN and LICENSEE desire to modify certain provisions of the License Agreement as provided herein. 

NOW THEREFORE, MICHIGAN and LICENSEE hereby agree as follows: 

1. Paragraph 4.3 is hereby deleted in its entirety. 

2. LICENSEE shall transfer to MICHIGAN 100,000 shares of its Series E preferred stock. LICENSEE represents and warrants that the price per
share of its Series E preferred stock is $ 0.25. LICENSEE shall make such transfer pursuant to, and subject to the terms of, a stock transfer agreement to be negotiated in good faith by the parties (the “STOCK TRANSFER AGREEMENT”). 

3. Except as specifically amended above, all other terms and conditions of the License Agreement remain unchanged and in effect and are hereby
ratified and adopted as though fully set forth herein. 
 IN WITNESS WHEREOF, the parties have entered into this Amendment to the Amended
Agreement as of the date and year first above-written. 
  

							
	CYTOPHERX, INC.	  	THE REGENTS OF THE UNIVERSITY OF MICHIGAN
				
	By:	  	 /s/ Charles J. Fisher, Jr.
	  	By:	  	 /s/ Kenneth J. Nisbet

	Title: Executive Chair & CEO	  	Title: Associate VP for Research, U-M Tech TransferEX-10.19

 Exhibit 10.19 

FIFTH AMENDMENT TO LICENSE AGREEMENT 

(University of Michigan Files 3718) 

This Amendment (“Amendment”), dated December 19 2019 (“Effective Date”), is by and between SeaStar Medical, Inc.
(“LICENSEE”) and the Regents of the University of Michigan (“MICHIGAN”). 
 WHEREAS, Cytopherx Inc. and MICHIGAN entered
into a License Agreement dated 16 October 2007, entered into a First Amendment dated 22 Mar 2011, entered into a Second Amendment dated 8 August 2013, entered into a Third Amendment dated 31 July 2014, and entered into a Fourth
Amendment dated June 20 2016 (collectively the “License Agreement”); 
 WHEREAS, Cytopherx Inc. changed its name to SeaStar
Medical, Inc. on or about June 20, 2018; and 
 WHEREAS, LICENSEE and MICHIGAN desire to modify certain provisions of the License
Agreement as provided herein; 
 NOW, THEREFORE, LICENSEE and MICHIGAN hereby agree as follows: 

1. Paragraph 5.2 is hereby deleted in its entirety and replaced with the following: 

Without limiting Paragraph 5.1, LICENSEE agrees to reach the following commercialization and research and development milestones for the
LICENSED PRODUCTS and LICENSED PROCESSES (together the “MILESTONES”) by the following dates: 
  

	 	1)	 Complete pediatric clinical trial by April 1 2020 

 

	 	2)	 Secure at least $5 million in funding (for pediatric device) by July 1 2020 

 

	 	3)	 Execute SCD manufacturing agreement/contract with Fresenius (or equivalent manufacturing partner) by
August 1 2020 

  

	 	4)	 Submit HDE submission with FDA by October 1 2020 (for pediatric device) 

 

	 	5)	 Initiate adult acute kidney injury device clinical trial by March 1 2021 

 

	 	6)	 Receive HDE clearance/approval for pediatric device from FDA by October 1 2021 

 

	 	7)	 FIRST COMMERCIAL SALE for pediatric device by January 1 2022 

 

	 	8)	 Submit for adult device FDA approval/clearance by March 1 2024 

 

	 	9)	 Receive adult device FDA approval/clearance by March 1 2025 

 

	 	10)	 FIRST COMMERCIAL SALE for adult device by June 1 2025 

 2. Except as specifically modified and amended above, all other terms and conditions of the
License Agreement remain unchanged and in effect and are hereby ratified and adopted as though fully set forth herein. 
 IN WITNESS
WHEREOF, the undersigned have duly executed this Fifth Amendment as of the date set forth above. 
  

							
	THE REGENTS OF THE UNIVERSITY OF MICHIGAN	  	SEASTAR MEDICAL, INC.
				
	By:	 	 /s/ Kelly B. Sexton, Ph.D.
	  	By:	  	 /s/ Eric Schlorff

	Title:	 	Associate Vice President for Research Tech Transfer and Innovation Partnership	  	Title: Interim CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00344-of-00352.parquet"}]]